Bacterial cultivation system, 9/17
September 2017—Advanced Instruments displayed its newly launched Anoxomat III at the 69th AACC Annual Scientific Meeting and Clinical Lab Expo in San Diego.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Ultra-sensitive POC test for GFAP, 9/17
September 2017—Dx-Sys has developed an ultra-sensitive, lateral flow point-of-care diagnostic test for glial fibrillary acidic protein, a potential biomarker for traumatic brain injury.
MDxHealth collaborations, 8/17
August 2017—MDxHealth has signed an exclusive licensing deal with Ghent University, Belgium, for its proprietary molecular diagnostic visualization technology that will allow the visual detection of epigenetic changes associated with cancer in tissue and liquid specimens.
Multigene panel testing for hereditary cancer risk, 8/17
August 2017—Myriad Genetics announced results from Study 005, a large 2,000 patient prospective study of the Myriad myRisk Hereditary Cancer test, which were featured in three poster presentations at the American Society of Clinical Oncology annual meeting in June.
SeraCare releases v2 NGS QC software , 8/17
August 2017—SeraCare Life Sciences launched iQ NGS QC Management v2, data management software that supports whole-workflow data capture from sample preparation to variant calling along with associated reagent and operator data. The software enables laboratories to re-create their QC workflows, set up their critical quality control metrics in the software, and have the data imported automatically using the new iQ Connector API—all to provide real-time insights into performance.
Molecular assay for C. diff, 8/17
August 2017—Quidel received 510(k) clearance to market its Solana C. difficile Assay for the direct, qualitative detection of Clostridium difficile DNA in unformed stool specimens of patients suspected of having Clostridium difficile infection.
Antimicrobial testing standards, 8/17
August 2017—The Clinical and Laboratory Standards Institute has published a revised edition of “M100: Performance Standards for Antimicrobial Susceptibility Testing, 27th ed.,” its annual supplement that provides revised breakpoints, new testing recommendations, and reporting changes needed to incorporate into routine practice.
Improved urinalysis control, 8/17
August 2017—Streck UA-Cellular Complete, a comprehensive cellular and chemistry analyte urinalysis control, is an integrated urinalysis control for the Siemens Clinitek Atlas/Sysmex UF-1000i and Arkray Aution Hybrid AU-4050 integrated systems. UA-Cellular Complete features true cellular components (no latex or other synthetic material) and provides three concentrations of combined urinalysis control to represent the various patient sample scenarios.
Gene and cell therapy platform, 8/17
August 2017—Horizon Discovery announced progress of its gene and cell therapy platform for contract service and therapeutic applications. The offering will make use of Horizon’s suite of gene editing technologies, including CRISPR and its proprietary rAAV and Transposon technologies, to edit pluripotent stem cells and primary human lymphocytes.
Fully automated LC-MS/MS analyzer, 8/17
August 2017—Thermo Fisher Scientific introduced its Thermo Scientific Cascadion SM Clinical Analyzer at EuroMedLab 2017 in Athens, Greece.